iRhythm Technologies (IRTC) Priced

Provides a device and analysis for detecting cardiac arrhythmias.

Health Care - Health Care Equipment & Supplies

IPO Performance
Latest Trade $38.25 0.00 (0.0%)
First Day Return 53.2%
Return from IPO 125.0%
 
iRhythm Technologies IPO News more
  • .
IPO Data
IPO File Date 09/23/2016
Offer Price $17.00
Price Range $13.00 - $15.00
Offer Shares (mm) 6.3
Deal Size ($mm) 107
 
IPO Data
IPO Date 10/19/2016
Offer Price $17.00
Price Range $13.00 - $15.00
Offer Shares (mm) 6.3
Deal Size ($mm) $107
 
Underwriters
more
Business Overview
We are a commercial-stage digital healthcare company redefining the way cardiac arrhythmias are clinically diagnosed by combining our wearable biosensing technology with cloud-based data analytics and machine-learning capabilities. Our goal is to be the leading provider of first-line ambulatory electrocardiogram, or ECG, monitoring for patients at risk for arrhythmias. We have created a unique platform, called the ZIO Service, which combines an easy-to-wear and unobtrusive biosensor that can be worn for up to 14 days, called the ZIO Patch, with powerful proprietary algorithms that distill data from millions of heartbeats into clinically actionable information. We believe that the ZIO Service allows physicians to diagnose many arrhythmias more quickly and efficiently than traditional technologies and avoid multiple indeterminate tests. Early detection of heart rhythm disorders such as atrial fibrillation, or AF, and other clinically relevant arrhythmias, allows for appropriate medical intervention and helps avoid more serious downstream medical events, including stroke. Since receiving U.S. Food and Drug Administration, or FDA, clearance in 2009, we have provided the ZIO Service to over 500,000 patients and have collected over 125 million hours of curated heartbeat data, creating what we believe to be the world’s largest repository of ambulatory ECG patient data. This data provides us with a competitive advantage by informing our proprietary machine-learned algorithms, which may enable operating efficiencies, gross margin improvement and business scalability. We believe the ZIO Service is well aligned with the goals of the U.S. healthcare system: improving population health, enhancing the patient experience and reducing per-capita cost.
We are a commercial-stage digital healthcare company redefining the way cardiac arrhythmias are clinically diagnosed by combining our wearable biosensing technology with cloud-based data analytics and machine-learning capabilities. Our goal is to be the leading provider of first-line ambulatory electrocardiogram, or ECG, monitoring for patients at...
more
Company Data
Headquarters San Francisco, CA
Founded 2006
Employees 373
Website www.iRhythmTech.com
 

Performance vs. IPO Index (IPOUSA)